Home Cart Sign in  
Chemical Structure| 932372-01-5 Chemical Structure| 932372-01-5

Structure of Asapiprant
CAS No.: 932372-01-5

Chemical Structure| 932372-01-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.

Synonyms: S-555739

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Asapiprant

CAS No. :932372-01-5
Formula : C24H27N3O7S
M.W : 501.55
SMILES Code : O=C(O)COC1=CC(N2CCN(S(=O)(C3=CC=C(OC(C)C)C=C3)=O)CC2)=CC=C1C4=NC=CO4
Synonyms :
S-555739
MDL No. :MFCD28902252
InChI Key :ZMZNWNTZRWXTJU-UHFFFAOYSA-N
Pubchem ID :59232326

Safety of Asapiprant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Asapiprant

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice SARS-CoV-2 infection model Oral 30 mg/kg Once daily, starting at 2 dpi and lasting for 6 days To evaluate the protective effect of Asapiprant against SARS-CoV-2 infection. Results showed that Asapiprant significantly reduced mortality (from 100% to <10%), mitigated weight loss, accelerated viral clearance, and reduced lung pathological changes. Nature. 2022 May;605(7908):146-151
Mice Streptococcus pneumoniae infection model Oral 30 mg/kg First dose at 12 h postinfection, then every 24 h To evaluate the therapeutic efficacy of asapiprant against Streptococcus pneumoniae infection. Results showed that asapiprant significantly reduced disease severity, systemic spread, and host death, enhanced antimicrobial activity in circulating neutrophils, elevated ROS levels in lung macrophages/monocytes, and improved pulmonary barrier integrity. Infect Immun. 2024 May 7;92(5):e0052223

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.97mL

1.99mL

1.00mL

19.94mL

3.99mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories